Pulmonary Hypertension – Landscape & Forecast – Disease Landscape & Forecast
Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality and no cure. Despite the rarity of the disease, the potential commercial opportunities for drugs approved for PH are considerable, driven by premium pricing and the likelihood of polypharmacy. Although this market has become congested, commercial interest in PH remains high owing to the need for more-efficacious and disease-modifying agents, as well as the lack of approved treatment options for unserved populations.
Questions answered
- Novel agents such as Merck & Co.’s sotatercept, United Therapeutics’ ralinepag, and Gossamer Bio’s seralutinib are in late-phase development for PH. What do interviewed thought leaders say about the advantages and disadvantages of these therapies? How will the launch of these agents affect prescribing decisions?
- Generic formulations have launched for several key branded therapies in recent years. How have these launches influenced prescribing patterns? What effect have generic launches had on entrenched brands, and what will be their impact on the performance of emerging therapies?
- A large unmet need exists for the treatment of PH WHO groups 2, 3, and 5. What are the other key unmet needs in PH? How likely are these unmet needs to be fulfilled during the forecast period?
- Patients with pulmonary arterial hypertension are typically prescribed PDE-5 inhibitors and/or ERAs as first-line therapy. What are the prescribing considerations dictating physician preferences for later-line treatments, and how do they vary between countries/geographical regions?
Content highlights
Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Key drugs covered: Uptravi, Orenitram, Adempas, Opsumit, Adcirca, Tracleer, Revatio, Letairis / Volibris, Remodulin, Flolan, Veletri, Tyvaso, Ventavis, Beraprost, ralinepag, Yutrepia, Tyvaso DPI, sotatercept, seralutinib, macitentan / tadalafil FDC.
Key companies mentioned: Johnson & Johnson, United Therapeutics, Bayer HealthCare, GlaxoSmithKline, Gilead Sciences, Pfizer, MannKind Corporation, Merck & Co., Liquidia Technologies, Gossamer Bio.
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Pulmonary Hypertension - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Key updates
- Market outlook
- Key findings
- Market drivers and constraints
- What factors are driving the market for pulmonary hypertension?
- What factors are constraining the market for pulmonary hypertension?
- Overall pulmonary arterial hypertension sales and patient share by drug class: 2022-2032
- Overall pulmonary arterial hypertension market by functional class: 2022-2032
- Overall pulmonary arterial hypertension sales by region: 2022-2032
- Overall pulmonary arterial hypertension patient share by brand / generic: 2022-2032
- Overall inoperable chronic thromboembolic pulmonary hypertension sales and patient share: 2022-2032
- Overall inoperable chronic thromboembolic pulmonary hypertension sales by region: 2022-2032
- Overall inoperable chronic thromboembolic pulmonary hypertension patient share by brand / generic: 2022-2032
- Overall pulmonary hypertension due to interstitial lung disease sales and patient share: 2022-2032
- Overall pulmonary hypertension due to interstitial lung disease sales by region: 2022-2032
- Overall pulmonary hypertension due to interstitial lung disease patient share by brand / generic: 2022-2032
- Drug-class-specific trends
- Forecast
- Market Forecast Downloads
- Market forecast assumptions: pulmonary arterial hypertension
- Market forecast dashboard: pulmonary arterial hypertension
- Market forecast assumptions: inoperable chronic thromboembolic pulmonary hypertension
- Market forecast dashboard: inoperable chronic thromboembolic pulmonary hypertension
- Market forecast assumptions: pulmonary hypertension-interstitial lung disease
- Market forecast dashboard: pulmonary hypertension-interstitial lung disease
- Etiology and pathophysiology
- Epidemiology
- Key findings
- Epidemiology populations
- Diagnosed prevalent cases of pulmonary hypertension (all causes)
- Diagnosed prevalent cases of pulmonary arterial hypertension
- Diagnosed prevalent cases of pulmonary hypertension due to left heart disease
- Diagnosed prevalent cases of pulmonary hypertension due to lung diseases and/or hypoxia
- Diagnosed prevalent cases of chronic thromboembolic pulmonary hypertension
- Diagnosed prevalent cases of pulmonary hypertension due to inoperable chronic thrombotic and/or embolic pulmonary hypertension
- Diagnosed prevalent cases of pulmonary hypertension due to miscellaneous causes
- Diagnosed prevalent cases of pulmonary arterial hypertension by functional class
- Diagnosed prevalence of pulmonary hypertension due to left heart disease by subgroup
- Diagnosed prevalence of pulmonary hypertension due to lung disease by subgroup
- Drug-treated cases of pulmonary hypertension
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for pulmonary hypertension
- Current treatments used for pulmonary hypertension
- Market events impacting the use of key current therapies for pulmonary hypertension
- Endothelin receptor antagonists
- PDE-5 inhibitors
- Prostacyclin analogues
- Soluble guanylate cyclase stimulators
- Medical practice
- Key findings
- Unmet need overview
- Drug pipeline
- Emerging therapies
- Key findings
- Key emerging therapies
- Key therapies in development for pulmonary hypertension
- Estimated launch dates of key emerging therapies for the treatment of pulmonary hypertension
- TGF-u03b2 ligand trap
- Prostacyclin analogues
- Endothelin receptor antagonist / phosphodiesterase-5 inhibitor fixed-dose combinations
- Tyrosine kinase inhibitors
- Early-phase pipeline analysis
- Key discontinuations
- Key findings
- Access and reimbursement
- Methodology
- Appendix
Sayani Datta, M.Sc., Manager – Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders. At Clarivate, Sayani’s primary areas of focus are nonalcoholic steatohepatitis (NASH) and pulmonary hypertension (PH). Previously, she was an associate consultant with IQVIA. She has worked on diverse types of custom and syndicated research projects in several therapeutic areas and has experience in sales- and epidemiology-based forecasting, commercial opportunity assessments, and market tracking and intelligence. She is an M.Sc. in biotechnology from the University of Leeds and gained exposure to life sciences research and development working as a postgraduate research intern.
Ullas Ulahannan, MPH., Epidemiologist, Epidemiology. Before joining Clarivate, he worked at Jhpiego (a John Hopkins University affiliate) as a senior program officer evaluating, implementing, and monitoring various health programs in collaboration with the state and central governments of India. His qualifications include a master’s degree in public health from Manipal University, Manipal, and a bachelor’s degree in nursing from Rajiv Gandhi University of Health Sciences, Bangalore